- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03131024
Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects (CREATE)
The Effects of Short-term Exercise or Caloric Restriction on Anthracycline Chemotherapy-related Treatment Toxicity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Research Question: Is there a practical, widely available, non-pharmacological intervention that can be used to reduce the detrimental effects of anthracycline treatment to improve breast cancer patient cardiovascular health, well-being?
Primary Hypothesis: short-term application of aerobic exercise or caloric restriction prior to anthracycline chemotherapy treatments for breast cancer will reduce the detrimental effects of anthracyclines on heart, vessels and skeletal muscle.
Exploratory Hypothesis: these interventions will enhance the anticancer effects of anthracyclines and/or reduce the detrimental effects of anthracyclines on health-related quality of life.
Primary Study Aims: to investigate the effect of a single aerobic exercise session performed 24 hours prior to anthracycline treatment and the effect of 50% caloric restriction for 48 hours prior to anthracycline treatment relative to usual care control. Specifically, we will measure the intervention effects on:
I) Cardiac structure and function: 1) circulating NT-proBNP (interventions will mitigate unwanted increase in this prognostic marker of development of later cardiotoxicity); 2) left ventricular ejection fraction reserve (interventions will mitigate unwanted reduction in ability to augment heart function with exercise challenge) and 3) cardiac T1 mapping (interventions will mitigate unwanted increase in this marker of formation of myocardial fibrosis)
II) Vascular Function: 1) Aortic distensibility (rest) (interventions will mitigate unwanted increase in vascular stiffness)
III) Skeletal Muscle Structure and Function: 1) skeletal muscle oxygen consumption 2) skeletal muscle oxygen extraction (interventions will mitigate unwanted loss of oxygen consumption, extraction at peak exercise and in recovery) and 3) skeletal muscle mass and quality (interventions will mitigrate unwanted loss of skeletal muscle mass and quality).
Exploratory Study Aims: to investigate the effects of these interventions relative to the control group on: 1) tumor size at end of treatment in neoadjuvant patients (interventions will reduce tumor size) and 2) quality of life and fatigue at end of treatment and one year after treatment (interventions will improve quality of life and fatigue) and 3) long-term clinical cardiac and cancer outcomes.
Design and Recruitment:
This study will be a three-arm randomized control trial of fifty-six early stage breast cancer patients receiving adjuvant or neoadjuvant anthracycline-containing chemotherapy treatment. Following completion of the baseline assessment, participants will randomized to one of three groups who will: 1) complete a supervised vigorous intensity aerobic exercise session 24 hours prior to each anthracycline treatment; 2) restrict their caloric intake by 50% for 48 hours prior to each treatment; or 3) control condition receiving oncological usual care only. Participants will be recruited via oncologist referral from the Cross Cancer Institute.
Sample Size Determination:
Cardiac MRI is extremely reproducible and thus sensitive to detecting change in ejection fraction. It has been previously demonstrated that n=15 patients are required to detect a 3 percentage point change of resting ejection fraction with cardiac MRI, an 85% reduction in sample size required to detect the same change using echocardiography. Using a n=15 sample size per group for a three-arm, three-repeated measures design, there is >90% power to detect a medium effect size at p=0.05 (G*Power Version 3.0.10, F-test with repeated measures and a within-between factor design). The primary outcome in the current study, ejection fraction reserve (peak ejection fraction minus resting ejection fraction) is expected to be more sensitive than resting ejection fraction and therefore this sample size is expected to detect a difference between the intervention groups and the control group. We will enrol n=56 total (n=18-19 per group) to allow for a 20% rate for dropout, death, and technical difficulties.
Statistical Methods:
Given the longitudinal study design with data collected at 3 time points for each subject, a linear mixed model analysis that includes both fixed and random effects, with an intention to treat approach will be used. The repeated measures on a single subject result in correlated outcome data, and the random effects allow this correlation to be explicitly modeled. An additional advantage is that it allows for missing data on a subject without deleting all the data for that subject. The model also allows for covariates to be tested and can include time varying covariates (e.g. treatments received post anthracyclines). One assumption of mixed models is that the residuals from the model are normally distributed. Pilot data indicates that this assumption will hold for this study. If that is not the case, a Generalized Linear Mixed Model analysis, which can fit other distributions, will be used. All analyses will be performed using SPSS 24.0.
An interim analysis of resting ejection fraction only (standard parameter used to monitor cardiotoxicity within oncology practice) will be completed by a paid statistician not associated with the study. Resting ejection fraction will be compared between groups after completion of the end of treatment assessment for the first thirty participants. A second interim analysis will be performed upon suggestion by the statistician.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Amy A Kirkham, PhD
- Phone Number: 780-492-8665
- Email: amy.kirkham@ualberta.ca
Study Contact Backup
- Name: Richard Thompson, PhD
- Phone Number: 7804928665
- Email: richard.thompson@ualberta.ca
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2R3
- University of Alberta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age 18+
- Female
- stage I-IIIC breast cancer
- scheduled to receive an anthracycline-containing chemotherapy protocol
- able to read and communicate in English
- willing and able to adhere to either intervention
Exclusion Criteria:
- contraindications to MRI (e.g. pacemakers, metal implants)
- contraindications to maximal exercise testing
- pregnant
- have orthopedic limitations to sustained exercise on all potential modes (treadmill, elliptical, bike)
- have a body mass index <19 kg/m2
- history of eating disorder (self- or oncologist-reported)
- diabetes
- severe food allergies or restrictions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aerobic exercise
The exercise arm includes a single bout of supervised treadmill walking scheduled such that it would end approximately 24 hours prior to each of the participant's scheduled anthracycline treatment time.
|
The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
|
Experimental: 50% caloric restriction
The caloric restriction arm will restrict their total caloric intake by 50% for 48 hours prior to each anthracycline treatment.
|
Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours
|
No Intervention: Usual care
The usual care arm will be asked to maintain their typical exercise and diet throughout treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in left ventricular ejection fraction reserve (peak exercise - rest)
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Cine steady-state free precession 2- and 4- chamber images will be taken at rest and at peak exercise using a resisted stepping device with a 3 T MRI scanner
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in NT-proBNP
Time Frame: 3-14 days before first anthracycline treatment, 24 hours after 1st and last anthracycline treatments, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
NT-proBNP will be analyzed in serum using electrochemiluminescence sandwich immunoassays
|
3-14 days before first anthracycline treatment, 24 hours after 1st and last anthracycline treatments, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in aortic distensibility
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Transverse cine images of the ascending and descending aorta will be taken with a 3 T MRI scanner
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in skeletal muscle oxygen extraction reserve (peak exercise - rest)
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Susceptometry-based oximetry using deoxyhemoglobin as an intrinsic contrast agent measured at rest and at peak exercise using a resisted plantar flexion device with a 3 T MRI scanner
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in skeletal muscle oxygen consumption reserve (peak exercise - rest)
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Susceptometry-based oximetry using deoxyhemoglobin as an intrinsic contrast agent, coupled with phase contrast imaging for simultaneous measurement of lower leg blood flow, will together yield oxygen consumption, which will be measured at rest and at peak exercise using a resisted plantar flexion device with a 3 T MRI scanner
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in resting LV strain
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Strain will be measured from cine steady-state free precession 2- and 4- chamber images will be taken at rest with a 3 T MRI scanner
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in peak exercise LV strain
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Strain will be measured from cine steady-state free precession 2- and 4- chamber images will be taken at peak exercise using a resisted stepping device with a 3 T MRI scanner
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in cardiac T1
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
T1 mapping will performed in a mid-ventricular short-axis slice using saturation recovery single-shot acquisition (SASHA) pulse and Modified Look-Locker inversion recovery (MOLLI) sequencing
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in peak LVEF
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Cine steady-state free precession 2- and 4- chamber images will be taken at peak exercise using a resisted stepping device with a 3 T MRI scanner
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Patient-reported treatment symptoms
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
The Rotterdam Symptom Checklist will be used to rate the prevalence and severity of treatment symptoms
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in cardiac output
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Cine steady-state free precession will be taken at rest and peak exercise to quantify volumes and will be multiplied by heart rate to determine cardiac output
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in LV volumes
Time Frame: Cine steady-state free precession will be taken at rest and peak exercise to quantify volumes and will be multiplied by heart rate to determine cardiac output
|
Cine steady-state free precession will be taken at rest and peak exercise to quantify volumes
|
Cine steady-state free precession will be taken at rest and peak exercise to quantify volumes and will be multiplied by heart rate to determine cardiac output
|
Change in resting LVEF
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Cine steady-state free precession 2- and 4- chamber images will be taken at rest
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in LV mass
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Mass will be measured using MRI
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in thigh skeletal muscle mass and quality
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Skeletal muscle mass of the thigh will be measured using Dixon fat-water separation imaging method that yields separated water and fat images to quantify skeletal muscle and adipose tissue.
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in peak oxygen consumption
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Peak oxygen consumption will measured using a maximal cardiopulmonary exercise test
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health-related quality of life and fatigue
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Health-related quality of life will be measured by the Functional Assessment of Cancer Therapy - Fatigue (FACT-F) questionnaire.
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment, one year after initiation of anthracycline treatment
|
Change in clinical tumor size
Time Frame: Anytime prior to inititiation of chemotherapy, and within 1 month of completion of chemotherapy or as otherwise clinically indicated
|
Clinical tumor size will be assessed using ultrasound in participants receiving neoadjuvant chemotherapy only
|
Anytime prior to inititiation of chemotherapy, and within 1 month of completion of chemotherapy or as otherwise clinically indicated
|
Combined clinical end-point
Time Frame: 1 and 5 years after completion of treatment
|
cancer recurrence, cardiac events, hospitalizations, and mortality will be extracted from clinical records and combined into a clinical end-point
|
1 and 5 years after completion of treatment
|
Change in circulating markers of oxidative stress/antioxidants
Time Frame: 3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment
|
ELISA assays will be used to measure circulating markers of oxidative stress such as MDA and antioxidants such as Mn-SOD.
Due to rapid development of these types of assays, samples will be frozen and will be run in batch analysis at the end of the study such that the most modern assays can be used.
|
3-14 days before first anthracycline treatment, 2-3 weeks after completion of anthracycline treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Amy A Kirkham, PhD, University of Alberta
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HREBA.CC-17-0129
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
-
University of ChicagoRecruitingBreast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIINigeria
-
Intuitive SurgicalRecruitingBreast Cancer | Breast Cancer Female | Breast | Breast Disease | Breast Cancer, Early-OnsetUnited States
Clinical Trials on Aerobic exercise
-
Riphah International UniversityCompleted
-
Sultan Abdulhamid Han Training and Research Hospital...RecruitingPhysical InactivityTurkey
-
University of FloridaAmerican Psychological Foundation; Clinical & Translational Science Institute; American Psychological Association (APA)CompletedBrain ConcussionUnited States
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)TerminatedChildhood ObesityUnited States
-
National Yang Ming UniversityUnknownKnee OsteoarthritisTaiwan
-
Radboud University Medical CenterUniversity Hospital, Bonn; University of Dublin, Trinity College; German Sport... and other collaboratorsCompletedMild Cognitive ImpairmentNetherlands, Ireland, Germany
-
National Defense Medical Center, TaiwanMinistry of Science and Technology, TaiwanRecruitingCardiology | PsychiatryTaiwan
-
Federal University of PelotasMinistry of Health, BrazilUnknownHypertension | Cardiovascular Disease | Chronic Kidney Disease | Chronic Renal DiseaseBrazil
-
University of Kansas Medical CenterRecruiting
-
Lithuanian University of Health SciencesCompletedMigraine | Temporomandibular Joint Disorders | Myofascial Trigger Point PainLithuania